A Clinical Study to Evaluate the Safety and Efficacy of Q-Fix Trial in Chinese Patients

Study Duration: 24 months = 12 months of recruitment + 12 months of follow up (From the start of screening to the time that the last subject completes the trial) Primary endpoint: Constant score at 6 months after operation for the shoulder Secondary endpoint(s): ASES score Rowe score WORC questionnaire Incidence of rotator cuff re-tear Recurrence rate of shoulder joint instability Anchor pullout rate Adverse event Radiographic evaluation results Constant score Safety Data AEs, SAEs, ADEs, UADEs

Inclusion criteria

• Male or female subjects, aged 18 - 75 years (inclusive at both ends), only of Chinese ethnicity.
• Patients with mature bones;
• Patients with rotator cuff tear and/or shoulder joint instability requiring arthroscopic treatment;
• Patients who are able to give voluntary and written informed consent to participate in the study and have signed EC-approved informed consent form.
• Patients who are able to understand this clinical study, co-operates with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups for up to 12 months.

Exclusion criteria

• Patients suffering from the rheumatic arthritis, tuberculosis of shoulder joint and infection around the shoulder joint;
• Patients with massive rotator cuff tear that can't be repaired;
• Patients who have received the rotator cuff surgery, arthroplasty of shoulder or surgical treatment of fracture for the shoulder joint at investigational side;
• Patients with a bone defect existing in the glenoid cavity that need the reconstruction of bony defect in the glenoid cavity;
• Patients that plan to receive the surgery for bilateral shoulder joint during the study;
• Patients suffering from the bone diseases with pathological characteristics, such as cystic changes or severe osteoporosis, that may affect the safe fixation of anchor in the investigator's opinion;
• Patients suffering from an active infection or sepsis (treated or untreated);
• Patients suffering from other diseases (e.g. epilepsy) that may affect the results of shoulder joint function;
• Patients that are known to be allergic to foreign body of materials of investigational product. If allergy to material is suspected, the corresponding test should be conducted and the possibility of allergy should be ruled out before implantation;
• Patients suffering from serious cardiovascular disease, liver and kidney diseases;
• Patients have an emotional or neurological condition that will affect their ability or willingness to participate in the study (e.g. cognitive disorder, mental illness, mental retardation).
• Patients are immunosuppressed, have an autoimmune disorder, or an immune dysfunction. For examples, patients are on immunosuppressive therapy (cortisol at large dose, cytotoxic drugs, antilymphocytic serum or irradiation at large doses);
• Patients are known to be at risk of being lost to follow-up, or failure to return to hospital for scheduled visits.
• Patients participated in another clinical study of investigational drug, biologic, or device in the last 12 months.
• Pregnant or lactating women, or those intend to become pregnant during the course of the study.
• Known alcohol and/or drug abuse.
• There are other serious or acute diseases, psychological conditions or social environment factors that may increase the risk of participating in the study or performing the surgery, or may reduce the reliability of participating in the study, or may increase the risk to the subjects themselves or others, in the investigator's opinion.